Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Felipe Samaniego*, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle Fanale, Loretta Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. Hagemeister, Nathan Fowler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences